Cargando…
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
[Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranos...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2015
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414921/ https://www.ncbi.nlm.nih.gov/pubmed/25843647 http://dx.doi.org/10.1021/nn507241v |
_version_ | 1782368997848645632 |
---|---|
author | Chen, Feng Hong, Hao Goel, Shreya Graves, Stephen A. Orbay, Hakan Ehlerding, Emily B. Shi, Sixiang Theuer, Charles P. Nickles, Robert J. Cai, Weibo |
author_facet | Chen, Feng Hong, Hao Goel, Shreya Graves, Stephen A. Orbay, Hakan Ehlerding, Emily B. Shi, Sixiang Theuer, Charles P. Nickles, Robert J. Cai, Weibo |
author_sort | Chen, Feng |
collection | PubMed |
description | [Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles. |
format | Online Article Text |
id | pubmed-4414921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-44149212015-12-14 In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine Chen, Feng Hong, Hao Goel, Shreya Graves, Stephen A. Orbay, Hakan Ehlerding, Emily B. Shi, Sixiang Theuer, Charles P. Nickles, Robert J. Cai, Weibo ACS Nano [Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles. American Chemical Society 2015-04-06 2015-04-28 /pmc/articles/PMC4414921/ /pubmed/25843647 http://dx.doi.org/10.1021/nn507241v Text en Copyright © 2015 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Chen, Feng Hong, Hao Goel, Shreya Graves, Stephen A. Orbay, Hakan Ehlerding, Emily B. Shi, Sixiang Theuer, Charles P. Nickles, Robert J. Cai, Weibo In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title | In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title_full | In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title_fullStr | In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title_full_unstemmed | In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title_short | In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine |
title_sort | in vivo tumor vasculature targeting of cus@msn based theranostic nanomedicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414921/ https://www.ncbi.nlm.nih.gov/pubmed/25843647 http://dx.doi.org/10.1021/nn507241v |
work_keys_str_mv | AT chenfeng invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT honghao invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT goelshreya invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT gravesstephena invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT orbayhakan invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT ehlerdingemilyb invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT shisixiang invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT theuercharlesp invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT nicklesrobertj invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine AT caiweibo invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine |